Claims

1. A composition comprising baclofen, D-sorbitol and naltrexone, salts, enantiomers, or racemates thereof, for simultaneous, separate or sequential administration to a mammalian subject.

2. The composition of claim 1, further comprising a pharmaceutically suitable excipient or carrier.

3. The composition according to claim 1 or 2, wherein said compounds are formulated with a biomolecule, a micelle or liposome-forming lipids or oil in water emulsions, or pegylated or solid nanoparticles or microparticles for oral or parenteral or intrathecal administration.

4. The composition of any one of the preceding claims, which is a liquid formulation suitable for oral administration.

5. Use of the composition of any one of claims 1 to 4, in the manufacture of a medicament for the treatment of Charcot Marie Tooth ("CMT") disease, a toxic neuropathy or Amyotrophic Lateral Sclerosis ("ALS") in a mammalian subject.

6. The use of claim 5, for the treatment of CMT1A in said mammalian subject.

7. The use of claim 5 or 6, wherein the mammalian subject is a human subject.

8. Use of Baclofen, D-sorbitol and naltrexone, salts, enantiomers, or racemates thereof in the manufacture of a medicament for the treatment of CMT disease, a toxic neuropathy or ALS in a mammalian subject, said medicament being formulated for simultaneous, separate or sequential administration.

Claims

1. A composition comprising baclofen, sorbitol and a compound selected from pilocarpine, methimazole, mifepristone, naltrexone, rapamycine, flurbiprofen and ketoprofen, salts, enantiomers, or racemates thereof, for simultaneous, separate or sequential administration to a mammalian subject.

2. The composition according to claim 1, wherein sorbitol is D-sorbitol.

3. The composition according to claim 1 or 2, comprising naltrexone, baclofen and D-sorbitol.

4. The composition of any one of the preceding claims, further comprising a pharmaceutically suitable excipient or carrier.

5. The composition according to any one of claims 1 to 4, wherein said compounds are formulated with a drug eluting polymer, a biomolecule, a micelle or liposome-forming lipids or oil in water emulsions, or pegylated or solid nanoparticles or microparticles for oral or parenteral or intrathecal administration.

6. The composition of any one of the preceding claims, for use in treating CMT, a toxic neuropathy or ALS.

7. The use of a composition of any one of the preceding claims for the manufacture of a medicament or treatment regimen for treating CMT, a toxic neuropathy or ALS.